ROSEN, SKILLED INVESTOR COUNSEL, Encourages Inovio Pharmaceuticals Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - INO
Rosen Law Firm is encouraging investors of Inovio Pharmaceuticals Inc. (NASDAQ: INO) to secure legal counsel before the April 7, 2026 deadline in a securities class action lawsuit. The lawsuit alleges that Inovio made false and misleading statements regarding deficiencies in its manufacturing process for the CELLECTRA device and the prospects of its INO-3107 Biologics License Application, causing investors to suffer damages. Investors who purchased Inovio securities between October 10, 2023, and December 26, 2025, may be eligible for compensation.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Inovio Pharmaceuticals Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - INO
Rosen Law Firm is encouraging investors of Inovio Pharmaceuticals Inc. (NASDAQ: INO) to secure legal counsel before the April 7, 2026 deadline in a securities class action lawsuit. The lawsuit alleges that Inovio made false and misleading statements regarding deficiencies in its manufacturing process for the CELLECTRA device and the prospects of its INO-3107 Biologics License Application, causing investors to suffer damages. Investors who purchased Inovio securities between October 10, 2023, and December 26, 2025, may be eligible for compensation.